This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gabazza, E. C. Articles by Suzuki, K. Search for Related Content PubMed Articles by Gabazza, E. C. Articles by Suzuki, K. Social Bookmarking                         What's this?

Acquired Activated Protein C Resistance in Patients with Lupus Anticoagulant and Essential Thrombocythemia

Department of Molecular Pathobiology, Mie University School of Medicine, Mie, Japan, Third Departments of Internal Medicine, Mie University School of Medicine, Mie, Japan

Hiroyuki Takeya, Ph.D.

Department of Molecular Pathobiology, Mie University School of Medicine, Mie, Japan

Hiroshi Deguchi, M.D.

Department of Molecular Pathobiology, Mie University School of Medicine, Mie, Japan

Osamu Taguchi, M.D.

Third Departments of Internal Medicine, Mie University School of Medicine, Mie, Japan

Hideo Wada, M.D.

Second, Mie University School of Medicine, Mie, Japan

Junji Nishioka, M.D.

Department of Molecular Pathobiology, Mie University School of Medicine, Mie, Japan

Hong Zhou, M.D.

Department of Molecular Pathobiology, Mie University School of Medicine, Mie, Japan

Koji Suzuki, Ph.D.

Department of Molecular Pathobiology, Mie University School of Medicine, Mie, Japan

The prevalence of activated protein C (APC) resistance and the antigen levels of factor V were assessed in 37 patients with lupus anticoagulant (LA), 12 with essential thrombocythemia (ET), 17 with idiopathic thrombocytopenic purpura (ITP), and in 27 cases of thrombotic complications associated with diabetes mellitus and collagen vascular disease. Blood samples taken from 30 healthy normal subjects were also available for comparison. The mean APC ratio of patients with LA (2.9 ± 1.5), ET (2.7 ± 1.2), and secondary thrombosis (2.6 ± 0.9) were significantly lower than that of the healthy control group (3.5 ± 1.0). The APC ratio of ET patients with thrombosis (2.3 ± 0.6) was significantly lower than that measured in ET cases without thrombotic complication (3.9 ± 1.9). Patients positive for LA and with thrombotic complication (1.8 ± 1.4) presented lower APC ratios than those without thrombosis (3.3 ± 1.4). Among all patients, an APC ratio lower than 2 was found in 24 cases, of which 16 had thrombotic disease, but none of them presented the factor V:R506Q mutation. The antigen levels of factor V correlated significantly with APC ratio in all patients. The results of this investigation suggest that an acquired poor anticoagulant response to APC might explain, at least in part, the thrombophilia of patients with LA and ET and that associated with diabetes mellitus or collagen disease. Key Words: APC resistance—Lupus anticoagulant—Essential thrombocythemia.

Clinical and Applied Thrombosis/Hemostasis, Vol. 3, No. 2, 119-123 (1997)
DOI: 10.1177/107602969700300209


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?